Growth on stiff substrate results in mild lifespan extension but a decrease in organismal health. by Maria Oorloff (19658113)

MRI imaging and analysis, revealing decreased volume and thickness of placentas exposed to intrauterine inflammation. by Solange N. Eloundou (6551627)

Elevated IDO activity in HD mouse brains is decreased by <i>ex-vivo</i> iron chelation. by David W. Donley (3111198)

“…</b> Striatal IDO activity is increased in N171-82Q HD mice and significantly decreased by <i>ex vivo</i> iron (III) chelation (50 μM deferoxamine). …”

High-Reflectivity Force-Chromic Photonic Crystal Elastic Materials Based on Nanospheres within an Elastomer for Applications in Sensing and Textile Fields by Zhichuang Qi (20539399)

Subjects:

High-Reflectivity Force-Chromic Photonic Crystal Elastic Materials Based on Nanospheres within an Elastomer for Applications in Sensing and Textile Fields by Zhichuang Qi (20539399)

Subjects:

High-Reflectivity Force-Chromic Photonic Crystal Elastic Materials Based on Nanospheres within an Elastomer for Applications in Sensing and Textile Fields by Zhichuang Qi (20539399)

Subjects:

Orsay virus infection of the <i>lin-8(n2731</i>) synMuv A mutant induces a Muv phenotype indicative of decreased synMuv B gene activity, and 2 different synMuv B mutants produce 50–100× less Orsay virus RNA. by Ashwin Seetharaman (615458)

Analysis of dpMPK-1 spatial expression in N2 <i>C</i>. <i>elegans</i> hermaphrodite germline after chronic exposure to IR at different life-stages. by Elizabeth Dufourcq Sekatcheff (17457627)

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma by Zhihao Liu (419349)

“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”

Spontaneous oxycodone withdrawal initially flattens NREM power rhythms, decreases low frequency and increases high frequency power. by Michael Gulledge (20577135)

Expanding Three-Coordinate Gold(I) Anticancer Agent Chemical Space by Charles E. Greif (21728091)

“…We report the synthesis and characterization of 14 complexes of the type (Au(R)[N̂N])⁺, where R = tunable biaryldialkyl phosphine ligands and [N̂N] = bidentate phenanthroline derivatives as anticancer agents. …”

Predictions of random forests (RF), gradient boosting machines (GBM), and neural networks (NN) trained on 12 covariates chosen using subjective feature selection. by Dennis Ochola (11626912)

Predictions of random forests (RF), gradient boosting machines (GBM), and neural networks (NN) trained on 17 covariates selected after recursive feature selection. by Dennis Ochola (11626912)

Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

Subjects:

Discovery of Triazolyl Derivatives of Cucurbitacin B Targeting IGF2BP1 against Non-Small Cell Lung Cancer by Fan-Fan Shang (16953264)

“…Derivative <b>A11</b> directly binds to the insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) protein with a <i>K</i>_D value of 2.88 nM, which is about 23-fold more potent than CuB, leading to the decreased expression of downstream apoptosis- and cell cycle-related proteins. …”

Mean observer DCCR (%) and DDR (%) at C3-4 in neutral and flexed neck positions in horses that were not operated (n = 18) versus were operated (n = 4) at this site. by Devon England (21262225)

Mean observer DCCR (%) and DDR (%) at C6-7 in neutral, flexed and extended neck positions in horses that were not operated (n = 13) versus operated (n = 9) at this site. by Devon England (21262225)

Mean observer DCCR (%) and DDR (%) at C5-6 in neutral, flexed and extended neck positions in horses that were not operated (n = 16) versus operated (n = 6) at this site. by Devon England (21262225)